

AMENDMENTS TO THE SPECIFICATION

Please amend the paragraph on page 12, lines 11-30, as follows:

The term "CD16" or "FcγRIII" are used interchangeably and refer to a cell surface receptor protein for a Fc portion of an IgG immunoglobulin. This receptor is a low affinity receptor for IgG and preferentially binds IgG in immune complexes. FcγRIII receptor is comprised of an a chain which serves as a ligand binding chain and a homodimer or heterodimer. When the FcγRIII is expressed on macrophages, the a chain is associated with a homodimer of the gamma chain. When the FcγRIII is expressed on natural killer cells, the α chain is associated with a heterodimer of the gamma chain with a delta chain. The gamma chain is involved in cell surface expression of the FcγRIII. "Naturally occurring CD16" has the amino acid sequence of cell surface receptor protein obtained from nature and includes naturally occurring variant forms including allelic variants, isotypes and truncated forms. Human CD16 includes all isotypes of the a chain including both CD16 or FcγRIII-A ~~FcγRIII-A~~ (GenBank Accession no. Z46222) and CD16 or FcγRIII-B (GenBank Accession no. Z46223). Representative amino acid and nucleotide sequences of the alpha chain of FcγRIII are shown in Figure 22A/B/C/D/E. Representative sequences for the human gamma chain are shown in Figure 25 (GenBank Accession No. P30273 and M33195). The invention also contemplates CD16 or FcγRIII variants. The variants are changed as compared to a source sequence by generally known techniques and preferably retain the biological activity of a naturally occurring human CD16 or FcγRIII. Some variants of FcγRIII are known to those of skill in the art.